Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;176(6):1617-1623.
doi: 10.1111/bjd.15235. Epub 2017 Apr 16.

Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists

K Taylor  1 , D J Swan  2 , A Affleck  3 , C Flohr  4 , N J Reynolds  2   5 ; U.K. Translational Research Network in Dermatology and the U.K. Dermatology Clinical Trials Network
Affiliations

Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists

K Taylor et al. Br J Dermatol. 2017 Jun.

Abstract

Background: Little is known about U.K. dermatologists' treatment approaches towards adult patients with recalcitrant moderate-to-severe atopic eczema.

Objectives: We wanted to learn about (i) treatment approaches used for this disease in the U.K.; (ii) factors that influence treatment decisions and (iii) perceived gaps in evidence on treatment safety and efficacy, and priorities for future trials.

Methods: We conducted an online survey of consultant-level dermatologists in the U.K.

Results: Sixty-one respondents from over 30 centres reported on management of moderate-to-severe atopic eczema in adults, outwith the context of an acute flare. Phototherapy or psoralen-ultraviolet A was the most common therapeutic modality chosen first line (46%), and this was usually narrowband ultraviolet B. Systemic therapy was chosen as a first-line approach by 36% of dermatologists. Azathioprine was the commonest drug reported being used as first line followed by oral corticosteroids, ciclosporin and methotrexate. Methotrexate was the most common second-line treatment of respondents. The key factors that influenced decision making on the use of phototherapy and systemic agents were the respondent's clinical experience, results of baseline tests (systemic agents) and knowledge of both efficacy and acute and chronic side-effect profiles. The most important evidence gaps identified were the relative effectiveness of treatments, the alternatives to current approaches and the safety of long-term maintenance treatment. With regard to future trials, respondents suggested that priority should be given to studies involving methotrexate.

Conclusions: While survey study designs have limitations, we found that phototherapy, in particular narrowband ultraviolet B, was respondents' preferred first-line treatment for adults with recalcitrant moderate-to-severe atopic eczema, perhaps reflecting access to, and clinical experience of, this approach. Azathioprine is widely used as a longer-term maintenance treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative reported priority for phototherapy selection by U.K. dermatologists in the management of moderate‐to‐severe atopic eczema in adults. UV, ultraviolet.
Figure 2
Figure 2
Relative reported priority of systemic therapies in the management of moderate‐to‐severe atopic eczema in adults.
Figure 3
Figure 3
(a) Average and (b) maximum duration of treatment reported by U.K. dermatologists for specified therapeutic agents.
See this image and copyright information in PMC

Comment in

References

    1. O'Donovan P, Perrett CM, Zhang X et al Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309:1871–4. - PMC - PubMed
    1. Proudfoot LE, Powell AM, Ayis S et al The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol 2013; 169:901–9. - PubMed
    1. Barker JN, Palmer CN, Zhao Y et al Null mutations in the filaggrin gene (FLG) determine major susceptibility to early‐onset atopic dermatitis that persists into adulthood. J Invest Dermatol 2007; 127:564–7. - PubMed
    1. Reynolds NJ, Franklin V, Gray JC et al Narrow‐band ultraviolet B and broad‐band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357:2012–16. - PubMed
    1. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate‐to‐severe atopic eczema: a double‐blind, randomised controlled trial. Lancet 2006; 367:839–46. - PubMed

Substances